



OPEN ACCESS

# Survival, hospitalisation and surgery in children born with Pierre Robin sequence: a European population-based cohort study

Michele Santoro ,<sup>1</sup> Ester Garne,<sup>2</sup> Alessio Coi,<sup>1</sup> Joachim Tan,<sup>3</sup> Maria Loane,<sup>4</sup> Elisa Ballardini,<sup>5</sup> Clara Caverro-Carbonell,<sup>6</sup> Hermien EK de Walle,<sup>7</sup> Miriam Gatt,<sup>8</sup> Mika Gissler,<sup>9,10</sup> Sue Jordan,<sup>11</sup> Kari Klungsoyr,<sup>12,13</sup> Natalie Lelong,<sup>14</sup> Stine Kjaer Urhoj ,<sup>2</sup> Diana G Wellesley,<sup>15</sup> Joan K Morris <sup>3</sup>

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/archdischild-2022-324716>).

For numbered affiliations see end of article.

## Correspondence to

Dr Michele Santoro, Institute of Clinical Physiology National Research Council, Pisa, 56124, Italy; [msantoro@ifc.cnr.it](mailto:msantoro@ifc.cnr.it)

Received 27 July 2022

Accepted 17 February 2023

## ABSTRACT

**Objective** To evaluate survival, hospitalisations and surgical procedures for children born with Pierre Robin sequence (PRS) across Europe.

**Design** Multicentre population-based cohort study.

**Setting** Data on 463 live births with PRS from a population of 4 984 793 from 12 EUROCAT congenital anomaly registries.

**Methods** Data on children with PRS born 1995–2014 were linked electronically to data on mortality, hospitalisations and surgical procedures up to 10 years of age. Each registry applied a common data model to standardise the linked data and ran common syntax scripts to produce aggregate tables. Results from each registry were pooled using random-effect meta-analyses.

**Main outcome measures** Probability of survival, proportion of children hospitalised and undergoing surgery, and median length of hospital stay.

**Results** The majority of deaths occurred in the first year of life with a survival rate of 96.0% (95% CI 93.5% to 98.5%); 95.1% (95% CI 92.7% to 97.7%) survived to age 10. In the first year of life, 99.2% (95% CI 95.0% to 99.9%) of children were hospitalised with a median stay of 21.4 days (95% CI 15.6 to 27.2), and 67.6% (95% CI 46.6% to 81.8%) underwent surgery. In the first 5 years of life, 99.2% of children underwent a median of two surgical procedures. Between ages 5 and 9, 58.3% (95% CI 44.7% to 69.7%) were hospitalised with a median annual stay of 0.3 days.

**Conclusions** Children with PRS had high mortality and morbidity with long hospital stays in the first year of life, and almost all had surgery before 5 years of age. Survival improved after infancy with fewer hospitalisations after age 5. This study provides reliable estimates of the survival and morbidity of children with PRS for families and healthcare providers.

## INTRODUCTION

Pierre Robin sequence (PRS) is a rare congenital anomaly (CA) characterised by three main clinical signs: micrognathia, glossoptosis and obstruction of the upper airway.<sup>1</sup> It is frequently associated with cleft palate.<sup>2</sup>

The European Network for the Surveillance of CAs (EUROCAT) estimates that the total prevalence of PRS is 12 per 100 000 births in the populations covered by EUROCAT registries, with

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Pierre Robin sequence (PRS) is a rare congenital anomaly with a prevalence of 12 per 100 000 births.
- ⇒ Respiratory disorders and feeding problems represent the main burden of the condition.
- ⇒ Many studies on PRS are limited to case series and often include only children referred to tertiary centres.

## WHAT THIS STUDY ADDS

- ⇒ This study is a population-based multicentre study of about 500 children born with PRS.
- ⇒ In the first year of life, 4.0% (95% CI 1.5% to 6.5%) of children died, but survival improved and 95.1% (95% CI 92.7% to 97.7%) survived to age 10 years.
- ⇒ Among children with PRS, 99% had surgery before 5 years of age.

## HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Results on several health outcomes provides information to evaluate the burden of PRS
- ⇒ Health outcome indicators provide useful information to support the healthcare system and the clinical management of children with PRS.

94.1% being live births. Among the liveborn children with PRS, 72% were isolated PRS; 5% were associated with a genetic syndrome, 5% with chromosomal anomalies and 18% with other structural CAs.<sup>3</sup> Respiratory disorders and feeding problems represent the main burden of the disease. Upper airway obstruction can occur with different levels of severity requiring different management. Airway obstruction is most dangerous during the first month, requiring close respiratory monitoring.<sup>4</sup> Feeding difficulties are thought to be secondary to both the airway obstruction and the associated cleft palate, leading to failure to thrive.<sup>5</sup>

Diagnosis and care of children with PRS require a multidisciplinary approach for surgical and non-surgical management.<sup>6–8</sup> A review by Côté *et al* reported that 68% of infants were successfully treated with non-surgical interventions (ie, prone



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

**To cite:** Santoro M, Garne E, Coi A, *et al*. *Arch Dis Child* Epub ahead of print: [please include Day Month Year]. doi:10.1136/archdischild-2022-324716

position, nasopharyngeal airway, orthodontic apparatus or continuous positive airway pressure).<sup>5</sup> Surgical procedures used to treat infants with major respiratory obstruction are tongue–lip adhesion and distraction osteogenesis of the mandible. For the most severely affected infants, tracheostomy may be needed.<sup>5–7 9</sup>

PRS is a rare disease with a high burden on affected children and their families.

The objectives of this study were

- ▶ To evaluate survival rates for children born with PRS across Europe.
- ▶ To evaluate rates and length of hospital stays for children born with PRS across Europe.
- ▶ To evaluate rates of surgical procedures performed on children born with PRS across Europe.

## METHODS

This is a EUROLINKCAT population-based data-linkage cohort study. The EUROLINKCAT project aimed to evaluate health outcomes in children with CAs up to 10 years of age by linking data on liveborn children registered in EUROCAT registries<sup>10 11</sup> to data in healthcare databases (eg, mortality, hospital admission and discharge data). Linked data were included up to the child's 10th birthday or to 31 December 2015 (whichever was earlier).<sup>12</sup> EUROCAT registries collect standardised data on all major CA cases in their population using multiple sources of ascertainment according to EUROCAT guidelines (EUROCAT Guide V.1.5, [https://eu-rd-platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration\\_en#inline-nav-2](https://eu-rd-platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration_en#inline-nav-2)). All registries with the ability and capacity to link to their mortality and hospital discharge databases were included in the EUROLINKCAT project.<sup>12</sup>

The study included data from 12 registries in nine European countries (table 1) covering different time periods between 1995 and 2014. The different time periods were due to registries

having different years of EUROCAT membership and that only years with good quality healthcare data and high levels of linkage were included.<sup>13</sup> Three registries (Norway, Wales and Malta) were national registries covering the whole country. Four registries covered all 20 birth years of the study period. All liveborn children with PRS during the specified birth years were included.

For the investigation of survival rates, data on mortality were obtained through linkage with vital statistics and mortality databases. A detailed description of the methods has been published elsewhere.<sup>14–16</sup>

Data on hospitalisations and surgical procedures were obtained by electronic linkage to the hospital databases used in the regions and countries covered by the registries. For three participating registries (ie, Paris, Norway and Malta), data on hospitalisations were not available for this study. Indicators of hospitalisation in children with PRS were compared with those in (1) all children born with any CA and (2) reference children without a CA, previously calculated by the EUROLINKCAT project.<sup>17</sup> Reference populations were all liveborn children without CAs from the same population covered by the registry in the same birth years. The Tuscany and Northern Netherlands registries used a random sample of their population (10% and 20%, respectively). No reference children were available for the three English registries. A detailed description of the EUROLINKCAT methods on hospitalisations has been published elsewhere.<sup>17</sup>

## Statistical analysis

The EUROLINKCAT common data model standardised the linked variables obtained by each participating registry. Common Stata syntax scripts were run by all registries to check the quality of data linkage and to analyse the data. Aggregated data and analytical results were uploaded to the Central Results Repository based at Ulster University (UK) and then transferred to the research team using a secure web platform.<sup>12</sup>

Within each registry, Kaplan-Meier survival analyses were performed to account for censoring, that is, children who were lost to follow-up due to death or emigration from the study area or who had not reached their 10th birthday by 31 December 2015. The Kaplan-Meier survival estimates with 95% CIs from each registry were combined in a random-effect meta-analysis using a modified method by Combesure *et al*<sup>18</sup> to estimate the overall survival for children with PRS at the following ages: 1 and 4 weeks and 1, 5 and 10 years. In addition, the 10-year survival conditional on having survived at 4 weeks was estimated.

The length of stay (LOS) in the hospital was calculated as the number of days spent in hospital between the date of admission and the date of discharge. For hospital stays in which the date of admission and discharge occurred on the same day, the LOS was considered to be 0.5 days. The median LOS per year, for those with at least one admission, was calculated within each registry and random-effect meta-analyses were performed using the 'metamedian' package in R V.4.0.3 for the following age groups: <1, 1–4 and 5–9 years. The aforementioned methods were also used to estimate the median age at first surgery and the median number of surgical procedures for the following age groups: <1, 1–4 and 0–4 years.

Within each registry, estimates for the percentage of children (1) hospitalised, (2) with a hospital stay longer than 10 days, (3) undergoing surgery, (4) undergoing surgery for gastrostomy (permanent feeding tube), (5) being admitted for intensive care and (6) being on a ventilator were obtained using Kaplan-Meier analyses. Random-effects meta-analyses were performed to provide overall estimates for age groups.

**Table 1** EUROCAT registries, birth years included, population covered and number of children with Pierre Robin sequence

Participating registries	Included birth years	Birth population covered*	Children with PRS (n)
Denmark: Funen	1995–2014	105 770	10
France: Paris†	1995–2014	597 822	87
Italy: Emilia Romagna	2008–2014	282 094	15
Italy: Tuscany	2005–2014	299 869	9
Malta†‡	1995–2014	84 737	10
Netherlands: Northern	1995–2014	372 192	45§
Norway†‡	1999–2014	956 939	35
Spain: Valencian Region	2007–2014¶	403 099	52
UK: East Midlands and South Yorkshire	2003–2012	717 264	47
UK: Thames Valley	2005–2013	270 327	34
UK: Wales‡	1998–2014	569 341	110
UK: Wessex	2004–2014	325 339	**
Total		4 984 793	463

\*Extracted from the EUROCAT website ([https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence\\_en](https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-data/prevalence_en)), accessed on 30 September 2021.

†Data on hospitalisation not available.

‡Whole nation covered.

§Number was rounded to the nearest 5 for the Northern Netherlands.

¶Study period for hospitalisation 2010–2014.

\*\*Not available due to small numbers.

EUROCAT, European Surveillance of Congenital Anomalies; PRS, Pierre Robin sequence.

**Table 2** Pooled survival estimates at selected age groups up to 10 years of age for children born with Pierre Robin sequence (n=463), 1995–2014

Age	Deaths (n)	Survival (%)	95% CI
1 week	1	99.7	99.2 to 100
4 weeks	7	98.8	97.6 to 100
1 year	21	96.0	93.5 to 98.5
5 years	26	95.3	92.9 to 97.7
10 years	26	95.1	92.7 to 97.7
10-year conditional on surviving to 4 weeks	19	96.3	93.5 to 97.9

## RESULTS

### Survival

A total of 463 children born with PRS from 12 EUROCAT registries covering a population of 4 984 793 births between 1995 and 2014 were included in the study (table 1). Among 463 children with PRS, a total of 26 deaths were observed during the study period. The majority of the deaths (21/26) occurred in the first year of life with an infant mortality rate of 4.0% (95% CI 1.5% to 6.5%). Survival was 99.7% (95% CI 99.2% to 100.0%) at 1 week, which dropped to 96.0% (95% CI 93.5% to 98.5%) at 1 year and to 95.1% (95% CI 92.7% to 97.7%) at 10 years of age (table 2). The probability of surviving to 10 years of age, having survived to 4 weeks, was 96.3% (95% CI 93.5% to 97.9%). Five-year survival estimates in the registries ranged from 84.6% (95% CI 71.6% to 92.0%) in the Valencian Region (Spain) to 100% (95% CI 66.4% to 100.0%) in Tuscany (Italy). The low precision of these estimates is due to the small numbers of events (online supplemental file 1).

### Hospitalisations

Data on hospitalisations were available for 306 children born with PRS in nine registries. Overall, 99.2% (95% CI 95.0% to 99.9%) were hospitalised in the first year, decreasing to 58.3% (95% CI 44.7% to 69.7%) at age 5–9 years (table 3). The percentage of children with PRS who were hospitalised is higher than that for children with any CA and for the reference children (figure 1).

In the first year of life, 66.2% (95% CI 51.8% to 77.1%) of children with PRS had at least one hospital stay longer than 10 days, which decreased to 13.1% (95% CI 1.0% to 41.1%) at 1–4 years (table 3). No long hospital stays were observed after 4 years of age. Compared with children with any CA,<sup>17</sup> these percentages are higher both in the first year of life (66.2% vs 23.9%) and at 1–4 years (13.1% vs 5.4%).

The median LOS was 21.4 days per year (95% CI 15.6 to 27.2) in children <1 year, 1.0 days (95% CI 0.7 to 1.3) in children 1–4 years and 0.3 days in children 5–9 years (95% CI 0.2 to 0.5).

### Surgery and other procedures

Data on surgery were available for 261 children born with PRS from eight registries. Overall 99.2% (95% CI 94.4% to 99.9%) of children underwent surgery in the first 5 years of life, while 67.6% (95% CI 46.6% to 81.8%) had surgery in the first year (table 4). The median number of surgical procedures in the first 5 years was 2.0 (95% CI 1.7 to 2.2). The median age at first surgery was 39.4 weeks (95% CI 32.1 to 46.4). In the first 5 years of life, 5.6% (95% CI 3.0% to 9.4%) received a gastrostomy for tube feeding.

Data on admissions to intensive care units (ICUs) were available for 71 children from seven registries. In the first 5 years of life, 22.6% (95% CI 12.9% to 34.0%) of children with PRS were admitted to the ICU. Data on the use of mechanical ventilation were available for 192 children from nine registries, which showed that 14.3% (95% CI 8.7% to 21.2%) of children with PRS had been on a ventilator in the hospital.

## DISCUSSION

This population-based cohort study reported on survival and hospitalisations of 463 children born with PRS in nine European countries, which is in contrast to many of the published studies on PRS limited to case series.<sup>19</sup> We were not able to analyse data separately for children with isolated PRS and those with associated anomalies. However, an estimated 72% of children were likely to have had isolated PRS, as observed in a recent EUROCAT study on the epidemiology of PRS which included most of the children in this study.<sup>3</sup>

### Survival

In our study, mortality was highest in the first year of life, with 4.0% (95% CI 1.5% to 6.5%) of children dying, but survival improved and 95.1% (95% CI 92.7% to 97.7%) survived to age 10. The early months of life represent the most critical time for children born with this rare anomaly. After infancy, we observed a good prognosis for these children.


Several published studies based on PRS case series have reported an infant mortality ranging from 1.7% to 4.1%, which is consistent with our estimate.<sup>20–23</sup> However, other studies have reported higher mortality: Logjes *et al* reported an overall mortality risk of 10% observed among about 100 patients in a hospital centre over a 20-year period. The same study reports that mortality was associated with syndromic cases and neurological anomalies.<sup>24</sup> Another study by Costa *et al* reported a mortality of 16.6% in 181 infants admitted to a neonatal intensive care

**Table 3** Percentage hospitalised, percentage with a long hospital stay (≥10 days) and median length of stay (LOS) per year of children with Pierre Robin sequence (n=306), by age, 1995–2014

Age (years)	Children with any hospitalisation			Children with a LOS over 10 days*			Median LOS	
	n	%	95% CI	n	%	95% CI	Days	95% CI
<1	293	99.2	95.0 to 99.9	127	66.2	51.8 to 77.1	21.4	15.6 to 27.2
1–4	213	76.7	64.3 to 85.2	12	13.1	1.0 to 41.1	1.0	0.7 to 1.3
5–9	90	58.3	44.7 to 69.7	0			0.3	0.2 to 0.5

\*Only children born at ≥37 weeks of gestation were included. Information on gestational age was not available from the Northern Netherlands, and their data were therefore excluded.

LOS, length of stay.



**Figure 1** Percentage hospitalised for children with PRS, children with any CA and children without a CA ('reference'), by age, 1995–2014. CA, congenital anomaly; PRS, Pierre Robin sequence.

unit (NICU),<sup>25</sup> a higher mortality in cases with associated anomalies and no deaths in isolated cases. The proportion of isolated cases observed in their study was lower than that observed in EUROCAT registries,<sup>3</sup> indicating that perhaps the healthier children with isolated PRS were not admitted to the NICU and hence were not included in the study.

### Hospitalisation

Almost all children with PRS were admitted to the hospital within the first year of life. The 0.8% without a hospital admission may have died shortly after birth and/or were not linked to the hospital databases. Hospital admissions reduced with age, but 60% of the children had at least one hospital admission at age 5–9 years with a much shorter median LOS compared with children admitted in the first year of life. The number of hospitalisations of children with PRS exceeded those for all children with any CA at all ages.

Stubenitsky *et al* reported that LOS was higher in children with respiratory disorders and feeding problems.<sup>26</sup> A study by Lee *et al* on infants admitted to a tertiary referral centre with

failure to thrive due to airway obstruction or feeding difficulties reported an average primary LOS of 64 days.<sup>8</sup> The widely different results between our study and the Lee study can be explained by the facts that the mean is calculated (rather than the median) and our cohort was population-based, including all children with PRS, not just those admitted to a tertiary centre.

### Surgery

Several studies have found that about 70% of children with PRS were successfully managed conservatively by use of appropriate positioning, without the need for early surgical treatment for airway obstruction.<sup>5 7 27</sup> Surgical treatment is needed for infants with moderate or severe airway obstruction who do not respond positively to positioning or other non-surgical treatments.<sup>5 6</sup> In our cohort, we observed that 67.6% of the children underwent surgery in the first year of life. Not all these children had surgery for airway obstruction as some children may have had surgery for closure of a cleft palate, which occurs in about 90% of children with PRS.<sup>3</sup> There is no clear consensus about the optimal age for surgery for cleft palate, as early surgery may have a negative impact of the maxilla, and late surgery may be associated with speech delays and difficulties.<sup>28 29</sup> Overall, 99% of the children in our study underwent surgery at least once before the age of 5 years and 61.1% after the first year. This proportion presumably included many operations for cleft palate.

Severe airway obstruction is associated with failure to thrive in children with PRS. Children with severe feeding difficulties who have failed to respond to conservative measures sometimes need the placement of gastrostomy tubes.<sup>30</sup> This procedure is less frequently used in isolated PRS.<sup>31</sup> In our cohort, a gastrostomy was needed for 5.6% of children with PRS.

**Table 4** Proportion of children with Pierre Robin sequence (n=261) undergoing surgery by age, 1995–2014\*

Age (years)	Children undergoing surgery (n)	Children undergoing surgery (%)	95% CI
<1	174	67.6	46.6 to 81.8
1–4	147	61.1	43.6 to 74.7
0–4	205	99.2	94.4 to 99.9

\*Data from Northern Netherlands were not available.



About 23% of the children were admitted to ICU and 14% needed a ventilator within the first 5 years. These children may represent the proportion of patients with major respiratory complications. These proportions are likely to be underestimated as there were some difficulties in defining the treatment codes used for the registration in the hospital databases. Furthermore, we did not have information about home mechanical ventilation. We are not aware of other studies that investigated ICU admissions or mechanical ventilation use.

Effective and timely clinical management, including an appropriate surgical treatment, is fundamental to ensure an adequate level of quality of life especially during childhood and adolescence.<sup>6 32</sup>

## Strengths

The main strength of this study is the population-based setting, which allows the inclusion of all children born with PRS and not only children referred to tertiary care centres as considered in many existing studies. Additionally, information on children with PRS were collected and validated by EUROCAT registries which have high levels of case ascertainment and use standardised definitions and coding of CAs to ensure consistency across Europe.

## Limitations

A limitation of the study is that isolated cases and associated cases of PRS could not be analysed separately due to the very small sample size in most of the registries. For the same reason, analyses by different time periods could not be performed.

Another limitation is that failure of linkage, occurring when an individual fails to be matched with the records in the health-care databases or is matched to the wrong record, could have produced bias in some outcomes. However, linkage failure is most likely to occur in the first days of life before the newborns have their permanent name or identification number.<sup>13</sup> As children with PRS have a high survival rate in the first days of life, the impact of this limitation is likely to have been minimal.

## CONCLUSIONS

Our study showed that the 10-year survival rate for children with PRS in Europe was more than 95%. However, these children have high morbidity, long hospital stays in the first year require surgery before 5 years of age. About 1 in 5 of the children have at least one admission to intensive care; 1 in 10 will need mechanical ventilation at least once; and 1 in 20 will need surgery for a permanent feeding tube. All these challenges carry inherent risks of complications and are a major burden for the child and the family. Efforts must be done to support these families throughout these children's childhood.

## Author affiliations

- <sup>1</sup>Unit of Epidemiology of rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy
- <sup>2</sup>Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark
- <sup>3</sup>Population Health Research Institute, St George's, University of London, London, UK
- <sup>4</sup>Faculty of Life and Health Sciences, Ulster University, Newtownabbey, UK
- <sup>5</sup>Neonatal Intensive Care Unit, Paediatric Section, IMER Registry (Emilia Romagna Registry of Birth Defects), Department of Medical Sciences, University of Ferrara, Ferrara, Italy
- <sup>6</sup>Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region FISABIO, Valencia, Spain
- <sup>7</sup>Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- <sup>8</sup>Directorate for Health Information and Research, Malta Congenital Anomalies Registry, G'mangia, Malta

- <sup>9</sup>Department of Knowledge Brokers, THL Finnish Institute for Health and Welfare, Helsinki, Finland
- <sup>10</sup>Region Stockholm, Academic Primary Health Care Centre, Stockholm, Sweden
- <sup>11</sup>Faculty of Medicine, Health and Life Science, Swansea University, Swansea, UK
- <sup>12</sup>Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway
- <sup>13</sup>Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Norway
- <sup>14</sup>Université de Paris, CRESS-Epopé, INSERM, INRA, Paris, France
- <sup>15</sup>Faculty of Medicine, University of Southampton and Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK

**Contributors** MS, EG, AC, JT, ML and JM had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: MS, EG, AC and JM. Development of study methods, including data standardisation and linkage, development of statistical analysis plan, writing of analysis programmes and statistical analysis: ML, MS, AC, JM, JT and EG. Drafting of the manuscript: MS, EG and JM. Obtaining of funding: JM, EG and ML. Supervision: JM. Data acquisition, interpretation of the results, critical revision of the manuscript for important intellectual content, approval the final manuscript as submitted and agreement to be accountable for major aspects of the work: all authors.

**Funding** This project received funding from the European Union's Horizon 2020 Research and Innovation programme (under grant agreement number 733001, January 2017–December 2021; <https://ec.europa.eu/programmes/horizon2020/en>).

**Competing interests** None declared.

**Patient consent for publication** Not applicable.

**Ethics approval** All registries contributing data to the EUROLINKCAT project already have ethical permission and procedures in place for registering cases of congenital anomalies (CAs) in their region according to their own national guidelines. Only one registry (Northern Netherlands (NNL)) requires informed consent to register a child with a CA. Approximately 20% of parents in NNL do not give their consent; hence, these children are not included in any study.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** No data are available. The data that support the findings of this study are available from the participating registries of congenital anomalies (CAs), but restrictions apply to the availability of these data, which were used under licence for the current study and so are not publicly available. However, data are available from the authors for scientifically valid requests and with permission from the participating registries of CAs.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## ORCID iDs

Michele Santoro <http://orcid.org/0000-0003-0676-3036>  
 Stine Kjaer Urhoj <http://orcid.org/0000-0002-2069-9723>  
 Joan K Morris <http://orcid.org/0000-0002-7164-612X>

## REFERENCES

- 1 Robin P. La chute de la base de la langue considérée comme une nouvelle cause de gêne dans la respiration naso-pharyngienne. *Bull Acad Med Paris* 1923;89:37.
- 2 Breugem CC, Evans KN, Poets CF, et al. Best practices for the diagnosis and evaluation of infants with Robin sequence: a clinical consensus report. *JAMA Pediatr* 2016;170:894–902.
- 3 Santoro M, Coi A, Barišić I, et al. Epidemiology of pierre-robin sequence in Europe: a population-based EUROCAT study. *Paediatr Perinat Epidemiol* 2021;35:530–9.
- 4 Wilson AC, Moore DJ, Moore MH, et al. Late presentation of upper airway obstruction in Pierre Robin sequence. *Arch Dis Child* 2000;83:435–8.
- 5 Côté A, Fanous A, Almajed A, et al. Pierre Robin sequence: review of diagnostic and treatment challenges. *Int J Pediatr Otorhinolaryngol* 2015;79:451–64.

- 6 Giudice A, Barone S, Belhous K, *et al.* Pierre Robin sequence: a comprehensive narrative review of the literature over time. *J Stomatol Oral Maxillofac Surg* 2018;119:419–28.
- 7 Gangopadhyay N, Mendonca DA, Woo AS. Pierre Robin sequence. *Semin Plast Surg* 2012;26:76–82.
- 8 Lee M, Ho ES, Forrest CR. Pierre Robin sequence: cost-analysis and qualitative assessment of 89 patients at the hospital for sick children. *Plast Surg (Oakv)* 2019;27:14–21.
- 9 Paes EC, Mink van der Molen AB, Muradin MSM, *et al.* A systematic review on the outcome of mandibular distraction osteogenesis in infants suffering Robin sequence. *Clin Oral Investig* 2013;17:1807–20.
- 10 Boyd PA, Haeusler M, Barisic I, *et al.* Paper 1: the EUROCAT network -- organization and processes. *Birth Defects Res A Clin Mol Teratol* 2011;91 Suppl 1:S2–15.
- 11 Kinsner-Ovaskainen A, Lanzoni M, Garne E, *et al.* A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU platform on rare diseases registration. *Eur J Med Genet* 2018;61:513–7.
- 12 Morris JK, Garne E, Loane M, *et al.* EUROLINKCAT protocol for a European population-based data linkage study investigating the survival, morbidity and education of children with congenital anomalies. *BMJ Open* 2021;11:e047859.
- 13 Loane M, Given JE, Tan J, *et al.* Linking a European cohort of children born with congenital anomalies to vital statistics and mortality records: a eurolinkcat study. *PLOS ONE* 2021;16:e0256535.
- 14 Glinianaia SV, Rankin J, Pierini A, *et al.* Ten-year survival of children with congenital anomalies: a European cohort study. *Pediatrics* 2022;149:e2021053793.
- 15 Santoro M, Coi A, Pierini A, *et al.* Temporal and geographical variations in survival of children born with congenital anomalies in Europe: a multi-registry cohort study. *Paediatr Perinat Epidemiol* 2022;36:792–803.
- 16 Coi A, Santoro M, Pierini A, *et al.* Survival of children with rare structural congenital anomalies: a multi-registry cohort study. *Orphanet J Rare Dis* 2022;17:142.
- 17 Urhoj SK, Tan J, Morris JK, *et al.* Hospital length of stay among children with and without congenital anomalies across 11 European regions-A population-based data linkage study. *PLoS One* 2022;17:e0269874.
- 18 Combescurre C, Foucher Y, Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. *Stat Med* 2014;33:2521–37.
- 19 Marston AP, Patel T, Pecha PP, *et al.* Impact of hospital characteristics on mandibular distraction osteogenesis outcomes among patients with Pierre Robin sequence utilizing a national inpatient database. *Cleft Palate Craniofac J* 2022;59:622–8.
- 20 van Nuen DPF, van den Boogaard M-J, Don Griot JPW, *et al.* Elevated infant mortality rate among Dutch oral cleft cases: a retrospective analysis from 1997 to 2011. *Front Surg* 2014;1:48.
- 21 Smith MC, Senders CW. Prognosis of airway obstruction and feeding difficulty in the Robin sequence. *Int J Pediatr Otorhinolaryngol* 2006;70:319–24.
- 22 Holder-Espinasse M, Abadie V, Cormier-Daire V, *et al.* Pierre Robin sequence: a series of 117 consecutive cases. *J Pediatr* 2001;139:588–90.
- 23 van den Elzen AP, Semmekrot BA, Bongers EM, *et al.* Diagnosis and treatment of the Pierre Robin sequence: results of a retrospective clinical study and review of the literature. *Eur J Pediatr* 2001;160:47–53.
- 24 Logjes RJH, Haasnoot M, Lemmers PMA, *et al.* Mortality in Robin sequence: identification of risk factors. *Eur J Pediatr* 2018;177:781–9.
- 25 Costa MA, Tu MM, Murage KP, *et al.* Robin sequence: mortality, causes of death, and clinical outcomes. *Plast Reconstr Surg* 2014;134:738–45.
- 26 Stubenitsky BM, Taylor HOB, Peters D, *et al.* Predictive value of weight gain and airway obstruction in isolated Robin sequence. *Cleft Palate Craniofac J* 2010;47:378–81.
- 27 Tomaski SM, Zalzal GH, Saal HM. Airway obstruction in the Pierre Robin sequence. *Laryngoscope* 1995;105:111–4.
- 28 Burg ML, Chai Y, Yao CA, *et al.* Epidemiology, etiology, and treatment of isolated cleft palate. *Front Physiol* 2016;7:67.
- 29 Harb JL, Crawford KL, Simmonds JC, *et al.* Race, income, and the timeliness of cleft palate repair in the United States. *Cureus* 2021;13:e13414.
- 30 Al-Attar H, Shergill AK, Brown NE, *et al.* Percutaneous gastrostomy tubes in children with Pierre Robin sequence: efficacy, maintenance and complications. *Pediatr Radiol* 2012;42:566–73.
- 31 Lidsky ME, Lander TA, Sidman JD. Resolving feeding difficulties with early airway intervention in Pierre Robin sequence. *Laryngoscope* 2008;118:120–3.
- 32 Thouvenin B, Soupre V, Caillaud M-A, *et al.* Quality of life and phonatory and morphological outcomes in cognitively unimpaired adolescents with Pierre Robin sequence: a cross-sectional study of 72 patients. *Orphanet J Rare Dis* 2021;16:442.

